NCT03433079

Brief Summary

Acute kidney injury (AKI) represents a serious complication following severe injury associated with adverse outcome. Main goals of the presented study were to define the incidence of AKI and to evaluate the validity of AKI biomarker neutrophil gelatinase-associated lipocalin (NGAL) in AKI prediction in severely injured patients. Secondary goals were to determine the time-dependent role of injury-related tissue hypoxia, systemic inflammatory response, and rhabdomyolysis in the pathophysiology of AKI.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
81

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2013

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2013

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2015

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2016

Completed
2 years until next milestone

First Submitted

Initial submission to the registry

February 7, 2018

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 14, 2018

Completed
Last Updated

February 14, 2018

Status Verified

February 1, 2018

Enrollment Period

2.6 years

First QC Date

February 7, 2018

Last Update Submit

February 7, 2018

Conditions

Keywords

Acute Kidney InjurySevere TraumaNGALTissue HypoxiaInflammatory ResponseRhabdomyolysis

Outcome Measures

Primary Outcomes (1)

  • Acute Kidney Injury biomarker validity

    The main goal of the study was to evaluate the validity of AKI biomarker neutrophil gelatinase-associated lipocalin in AKI prediction in severely injured patients with Injury Severity Score (ISS) \> 24.

    36 months

Secondary Outcomes (1)

  • Time-dependent role of insults

    36 months

Study Arms (1)

Acute Kidney Injury

Patients \> 18 years of age with acute kidney injury were enroled into the study. Arterial levels of neutrophil gelatinase-associated lipocalin (NGAL), arterial lactate, interleukin-6 (IL-6), procalcitonin (PCT) and myoglobin were investigated in all patients.

Diagnostic Test: Neutrophil gelatinase-associated lipocalin (NGAL)Diagnostic Test: Arterial lactateDiagnostic Test: Interleukin-6 (IL-6)Diagnostic Test: Procalcitonin (PCT)Diagnostic Test: Myoglobin

Interventions

Blood neutrophil gelatinase-associated lipocalin (NGAL) test was performed in all patients.

Acute Kidney Injury
Arterial lactateDIAGNOSTIC_TEST

Arterial lactate level was assessed in all patients.

Acute Kidney Injury
Interleukin-6 (IL-6)DIAGNOSTIC_TEST

The level of interleukin-6 was assessed in all patients.

Acute Kidney Injury
Procalcitonin (PCT)DIAGNOSTIC_TEST

The level of procalcitonin (PCT) was assessed in all patients.

Acute Kidney Injury
MyoglobinDIAGNOSTIC_TEST

The level of myoglobin was assessed in all patients.

Acute Kidney Injury

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Severely injured patients (ISS \> 24) older than 18 years.

You may qualify if:

  • \- severe injury (ISS \>24)

You may not qualify if:

  • age \< 18 years
  • history of kidney disease
  • pregnancy
  • death within 24 hours after injury
  • unsurvivable injury (withheld or withdrawn therapy) within 24 hours after injury
  • clinical signs of brain death within 24 hours after injury

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Ostrava

Ostrava, Moravian-Silesian Region, 70852, Czechia

Location

MeSH Terms

Conditions

Acute Kidney InjuryWounds and InjuriesRhabdomyolysis

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesMuscular DiseasesMusculoskeletal Diseases

Study Officials

  • Peter Sklienka, MD

    University Hospital Ostrava

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 7, 2018

First Posted

February 14, 2018

Study Start

June 1, 2013

Primary Completion

December 31, 2015

Study Completion

January 31, 2016

Last Updated

February 14, 2018

Record last verified: 2018-02

Locations